Return to report Abstract
| Executive Summary | 03 | |
| Setting the Stage | 05 | |
| Transaction Volume | 06 | |
| Exceptions the Norm | 07 | |
| Standards But No Standards | 09 | |
| Stakeholders | 11 | |
| Gradual Morphing of Stakeholders | 12 | |
| Acquisitions and Partnerships Triggering Change | 13 | |
| Change Agents | 15 | |
| athenahealth | 20 | |
| The Bank of New York Mellon | 23 | |
| InstaMed | 27 | |
| MedAvant Healthcare Solutions | 29 | |
| Misys Payerpath | 32 | |
| Payformance | 35 | |
| PNC | 38 | |
| RMS | 41 | |
| Breaking the Mold Through Cooperation | 44 | |
| Cooperation: Road to True Standards | 44 | |
| From the New Mold: e-Prescriptions | 45 | |
| Making an Uber Exchange Work: Lessons from Australia | 49 | |
| Glimmers of a New Order | 53 | |
| Appendix: Overview of the Healthcare Market | 56 | |
| Glossary | 57 | |
| Healthcare Expenditure Trends | 59 | |
| Complexities of Healthcare Processes | 59 | |
Celent is a research and advisory firm dedicated to helping financial institutions formulate comprehensive business and technology strategies. Celent publishes reports identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally experienced analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a member of the Oliver Wyman Group, which is part of Marsh & McLennan Companies [NYSE: MMC].
New York - Dana Lautin
dlautin@celent.com
Tel.: +1 646 364 8254
Paris - Muriel de Munck
mdemunck@celent.com
Tel.: +33 1 42 61 06 88
Tokyo - KyongSun Kong
kkong@celent.com
Tel.: +81 3 3596 0020